GlassScriptPhysician profile
Rajiv Arora
NPI 1689724155
$143,847.24
in general payments reported to CMS, 2019-2025
33 companies · $25K in 2025
The $25K reported for 2025 was more than what 93% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $10K · 2021: $13K · 2022: $13K · 2023: $29K · 2024: $36K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Food and Beverage: $4,686 · Travel and Lodging: $2,654 · Education: $80.80 · Consulting Fee: $14.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,523.75 |
| Food and Beverage | $4,686.48 |
| Travel and Lodging | $2,653.91 |
| Education | $80.80 |
| Consulting Fee | $14.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $59,218.81 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Genzyme Corporation | $46,975.38 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $34,716.01 | 2019-2025 | Dupixent |
| Csl Behring | $617.85 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Glaxosmithkline, LLC. | $421.19 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $293.08 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.57 | 2021-2024 | Cuvitru |
| Kaleo, INC. | $189.59 | 2019-2023 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $184.64 | 2019-2025 | |
| Genentech USA, INC. | $134.41 | 2021-2023 | Xolair |
| Amgen INC. | $96.26 | 2025 | Tezspire |
| Pharming Healthcare, INC. | $83.21 | 2020-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $81.81 | 2021-2022 | |
| Alk-Abello, INC | $66.21 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $57.51 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Cycle Pharmaceuticals INC | $52.28 | 2025 | Sajazir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.81 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $41.65 | 2020-2021 | |
| Abbvie INC. | $41.32 | 2022 | |
| Octapharma USA, INC. | $41.00 | 2022-2025 | Panzyga |
| Leo Pharma INC. | $22.69 | 2024 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $22.27 | 2025 | Neffy |
| Covis Pharma Gmbh | $22.21 | 2021 | |
| Ionis Pharmaceuticals, INC. | $21.76 | 2025 | Dawnzera |
| Uswm, LLC | $20.14 | 2021 | |
| Blueprint Medicines Corporation | $19.92 | 2024 | Ayvakit |
| Grifols USA, LLC | $18.68 | 2025 | Xembify |
| Biocryst Pharmaceuticals, INC. | $16.53 | 2020 | |
| Incyte Corporation | $15.14 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.95 | 2025 | Zoryve |
| Adma Biomanufacturing LLC | $14.56 | 2025 | |
| Optinose US, INC. | $14.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.